Research Analysts Issue Forecasts for Apogee Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:APGE)

Apogee Therapeutics, Inc. (NASDAQ:APGEFree Report) – Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Apogee Therapeutics in a research note issued to investors on Monday, May 13th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.63) per share for the quarter. Wedbush has a “Outperform” rating and a $87.00 price objective on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Apogee Therapeutics’ Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.65) EPS and Q4 2025 earnings at ($0.67) EPS.

Apogee Therapeutics (NASDAQ:APGEGet Free Report) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13.

A number of other brokerages have also weighed in on APGE. Jefferies Financial Group raised their target price on Apogee Therapeutics from $37.00 to $75.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Guggenheim raised their price target on shares of Apogee Therapeutics from $44.00 to $91.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Stifel Nicolaus upped their target price on shares of Apogee Therapeutics from $46.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Finally, Bank of America assumed coverage on shares of Apogee Therapeutics in a research note on Friday. They set a “buy” rating and a $80.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $73.00.

Get Our Latest Research Report on Apogee Therapeutics

Apogee Therapeutics Stock Down 0.9 %

NASDAQ APGE opened at $52.73 on Tuesday. Apogee Therapeutics has a 1-year low of $14.19 and a 1-year high of $72.29. The company has a 50 day moving average of $58.05 and a 200-day moving average of $38.06.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in APGE. Amalgamated Bank acquired a new position in Apogee Therapeutics in the 3rd quarter worth $52,000. Strs Ohio acquired a new stake in Apogee Therapeutics in the third quarter valued at $87,000. Ameritas Investment Partners Inc. increased its stake in shares of Apogee Therapeutics by 111.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock worth $274,000 after purchasing an additional 2,172 shares during the last quarter. New York State Common Retirement Fund acquired a new stake in Apogee Therapeutics in the 3rd quarter valued at about $90,000. Finally, SG Americas Securities LLC bought a new stake in Apogee Therapeutics in the third quarter valued at approximately $105,000. 79.04% of the stock is owned by institutional investors and hedge funds.

Apogee Therapeutics Company Profile

(Get Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Recommended Stories

Earnings History and Estimates for Apogee Therapeutics (NASDAQ:APGE)

Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.